MEK inhibitor resistance mechanisms and recent developments in combination trials

E Kun, YTM Tsang, CW Ng, DM Gershenson… - Cancer treatment …, 2021 - Elsevier
The mitogen-activated protein kinase (MAPK) pathway plays a vital role in cellular
processes such as gene expression, cell proliferation, cell survival, and apoptosis. Also …

Overcoming KRAS-Mutant Lung Cancer

J Luo, J Ostrem, B Pellini, D Imbody, Y Stern… - American Society of …, 2022 - ascopubs.org
More than 50 years after the discovery of RAS family proteins, which harbor the most
common activating mutations in cancer, the US Food and Drug Administration approved the …

Identification of an energy metabolism‑related gene signature in ovarian cancer prognosis

L Wang, X Li - Oncology reports, 2020 - spandidos-publications.com
Abstract Changes in energy metabolism may be potential biomarkers and therapeutic
targets for cancer as they frequently occur within cancer cells. However, basic cancer …

The anti-proliferative effect of PI3K/mTOR and ERK inhibition in monolayer and three-dimensional ovarian cancer cell models

E Dunn, K Chitcholtan, P Sykes, A Garrill - Cancers, 2022 - mdpi.com
Simple Summary In ovarian cancer patients the PI3K/AKT/mTOR and RAS/RAF/MEK/ERK
kinase signaling pathways are frequently dysregulated, making them potential targets of …

Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors

Y Gu, C Wei, M Chung, H Li, Z Guo, M Long, Y Li… - Frontiers in …, 2022 - frontiersin.org
Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft-tissue sarcomas
which lack effective drugs. Loss of the RAS GTPase-activating protein NF1 and subsequent …

Tumor immune microenvironment in brain metastases from gynecologic malignancies

CM Gill, MR D'Andrea, S Tomita, J Suhner… - Cancer Immunology …, 2021 - Springer
Introduction The density and distribution of the tumor immune microenvironment associated
with brain metastases (BM) from gynecologic malignancies are unknown and have not been …

Should we abandon hormonal therapy in endometrial cancer? Outcomes of recurrent and metastatic endometrial cancer treated with systemic progestins

A Kulkarni, NMA Wright, AN Forget, T Ramsay… - Cancer …, 2023 - Wiley Online Library
Purpose The objective of this study is to determine primary survival endpoints in women with
recurrent and metastatic endometrial carcinoma (RMEC) treated with progestins. Methods A …

MYC and HSF1 Cooperate to Drive PLK1 inhibitor Sensitivity in High Grade Serous Ovarian Cancer

I Williams, H DeHart, M O'Malley, B Walker… - bioRxiv, 2024 - biorxiv.org
Ovarian cancer is a deadly female cancer with high rates of recurrence. The primary
treatment strategy for patients is platinum-based therapy regimens that almost universally …